FDA approval is just the beginning. Now Lilly’s Kisunla faces the tough Alzheimer’s market.

Recent history suggests an Alzheimer’s approval doesn’t necessarily translate to market triumph. Perhaps for Eli Lilly’s Kisunla, this time could be different.